Mayne Pharma Group Ltd. · ASX:MYX
Mayne Pharma — JMP Securities Life Sciences Conference 2023
28 slides from Mayne Pharma's conference presentation, May 15, 2023
Slide 1: ASX Announcement: Mayne Pharma to present at JMP Securities Life Sciences Conference
ASX Announcement MAYNE PHARMA TO PRESENT AT JMP SECURITIES LIFE SCIENCES CONFERENCE ON 15 MAY 2023 IN NEW YORK CITY 15 May 2023, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) today announced that Shawn Patrick O’Brien, Chief Executive Officer of Mayne Pharma, will present at the JMP Sec
Slide 2: Mayne Pharma Group Limited - JMP Securities Life Sciences Conference
For personal use only Mayne Pharma Group Limited JMP Securities Life Sciences Conference May 15, 2023 Shawn Patrick O’Brien, CEO Aaron Gray, CFO
Slide 3: Disclaimer
Disclaimer The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s audited Financial Statements and market disclosures. This material is not intended to be relied upon as advice to investors or potential inves
Slide 4: A lot of change over the last 7+ months
For personal use only A lot of change over the last 7+ months A period of significant structural change to reset Mayne Pharma for profitable growth
Slide 5: Key Observations, Actions And Priorities
Key Observations, Actions And Priorities People, products, and processes focused on the needs of patients to drive growth ● Organisational realignment began with a new US focused leadership team For personal use only driven to create commercial and operational excellence ● PEOPLE: new leadership tea
Slide 6: Successful Execution of Strategy
Successful Execution of Strategy GOAL: Become a more focused business with significant growth opportunities For personal use only Invested in Capital Management Plan US Women’s Sale of US Sale of Health Retail ➢ Repayment of A$358.7m Metrics Generics to syndicated debt facilities ➢ Commercialization
Slide 7: Group Financial Overview
Group Financial Overview A$million1 1H23 1H22 1H23 v 1H22 For personal use only Reported Revenue 101.2 150.4 (33%) Reported Gross Profit 7.9 64.6 (88%) Reported EBITDA (99.2) 66.1 (250%) Reported Net Loss After Tax (129.2) (208.4) (38%) Underlying EBITDA2 (53.1) 63.5 (184%) Underlying EBITDA (excl.
Slide 8: Group Financial Overview
Group Financial Overview 1HFY23 2HFY22 1HFY22 Revenue Revenue Revenue For personal use only $26.8 $27.6 $28.6 $6.3 $4.2 Portfolio Products Branded Products International/Other $59.1 $13.4 $125.6 $118.6 Retail Retail Retail Generics: Generics: Generics: $48.0MM $75.5MM $76.9MM 7
Slide 9: Branded Products Division (BPD)
For personal use only Branded Products Division (BPD)
Slide 10: Branded Products Division (BPD)
Branded Products Division (BPD) NEXTSTELLIS® For personal use only ● NEXTSTELLIS® revenues were US$7.1m A$million 1H23 2H22 1H22 Reported revenue 13.4 6.3 4.2 - Up 123% on 2HFY22 (US$3.2m) Reported Gross Profit 10.7 5.1 3.3 - Up 567% on 1HFY22 (US$1.1m) Gross Profit % 80% 81% 79% ● NEXTSTELLIS® dire
Slide 11: Women's Health Acquisition: Accelerating Our Vision to Become a Leader
Women’s Health Acquisition: Accelerating Our Vision to Become a Leader For personal use only Prenatal Vitamins CONTRACEPTION/ DYSPAREUNIA CONTRACEPTION PRENATAL FAMILY PLANNING - VASOMOTOR (Vulvar & Vaginal CARE PERIMENOPAUSE SYMPTOMS Atrophy) REPRODUCTIVE HEALTH MENOPAUSE MANAGEMENT 10
Slide 12: Building a leading US Women's Health Business (BPD)
Building a leading US Women’s Health Business (BPD) Acquired Portfolio For personal use only Prenatal Vitamins REPRODUCTIVE HEALTH PRENATAL MENOPAUSE MANAGEMENT STRATEGIC PRIORITIES ✓ Successfully implement new commercial strategy for NEXTSTELLIS® to accelerate growth in the US and Australia ✓ Deliv
Slide 13: Building a leading US Women's Health Business (BPD)
Building a leading US Women’s Health Business (BPD) ● Infrastructure in place For personal use only - Experienced sales team of 100 (up from 86) able to reach our target customers - Refreshed team training initiative to improve sales productivity and impact - Full marketing mix to drive awareness an
Slide 14: NEXTSTELLIS Website traffic increasing with DTC campaign
NEXTSTELLIS® Website traffic increasing with DTC campaign MONTHLY NEXTSTELLIS.COM U.S. USERS 2023 vs. 2022 200,000 214,000 Projected May website traffic For personal use only 180,000 176,243 173,419 160,000 140,000 147,857 120,000 TV LAUNCH 13/2 100,000 109,210 80,000 60,000 40,000 48,487 20,000 - J
Slide 15: FY23 Q3 NEXTSTELLIS Field Activity up dramatically over Q2
FY23 Q3 NEXTSTELLIS® Field Activity up dramatically over Q2 For personal use only 14 NRx totals based on IQVIA Exponent Data adjusted for non-reporting pharmacies through 31Mar23
Slide 16: Portfolio Products Division (PPD)
For personal use only Portfolio Products Division (PPD)
Slide 17: Portfolio Products Division (PPD)
Portfolio Products Division (PPD) Dermatology ● Revenue and contribution materially impacted by inventory For personal use only A$million 1H23 2H22 1H22 work through following 2HFY22 sales activities Reported revenue 59.1 125.6 118.6 - 1HFY23 Revenue of US$7.5m down 80% on 2HFY22 sales Reported Gros
Slide 18: Overview of the US Dermatology Market
Overview of the US Dermatology Market Building market leadership and scale with pipeline of new products Proprietary Brands Specialty Partners For personal use only STRATEGIC PRIORITIES ✓ Build on strength of market position with strong, profitable pipeline of new products to meet broader patient ne
Slide 19: Dermatology – business performance improving
Dermatology – business performance improving; delivering on positive contribution margin ● Improving momentum following 1H-FY23 channel inventory issues which resulted in recalibration of pricing, GTN and lower volumes in some products For personal use only ● GTN and pricing has stabilised across ke
Slide 20: Dermatology Units growing and GTN stabilised
Dermatology Units growing and GTN stabilised For personal use only ● Growth expected from Q3-FY23 launches ● Gross sales increasing since August - DORYX® MPC 60 February 2023 ● Net Sales growth since October - gORACEA® March 2023 ● GTN stabilised in Q3 19
Slide 21: International
For personal use only International
Slide 22: International
International ● Good growth in international sales as product availability increases following early improvement in manufacturing and supply chain For personal use only performance A$million 1H23 2H22 1H22 ● KAPANOL® /KADIAN® (morphine) market expansion to treat Opioid Reported revenue 27.6 26.8 27.
Slide 23: International Improvement Initiatives
International Improvement Initiatives Manufacturing strategy focused on cost efficiency and reliable supply at the best quality • For personal use only Organisational design review completed and implemented, focus on key roles in supply chain • Implementation of lean practices and metrics underway t
Slide 24: Accelerating International Growth and Profitability
Accelerating International Growth and Profitability NEXTSTELLIS® launch in Australia Federal Government grant to modernise Salisbury For personal use only ● High Speed Encapsulator ● High Speed Blister Packing Line with Serialisation capabilities Continue growth of Australian based CDMO business ● D
Slide 25: Outlook
For personal use only Outlook
Slide 26: Strategic priorities for FY23 & FY24 to drive shareholder value
Strategic priorities for FY23 & FY24 to drive shareholder value # 1 Priority, B/E ASAP Deliver EBITDA Positive WH Improve Margin & Access Secure accretive assets Accelerate AU Growth For personal use only Successfully Successfully Deliver on the full US channel Broaden portfolio Continued commercial
Slide 27: Outlook
Outlook ● FY23 has been one of significant business transition with the completion of the sale of MCS and Retail Generics and the acquisition of the TXMD portfolio For personal use only ● Momentum continues to build across BPD/Women’s Health portfolio following acquisition and investment in new prod
Slide 28: Q&A
Q&A For personal use only You deserve tomorrow. 27
Mayne Pharma Group — JMP Securities Life Sciences Conference 2023 on 6ix